IONIS PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Plans
During the quarter ended December 31, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act), or Section 16 officers and directors, adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted in the table below.
Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
“Non-Rule 10b5-1 trading arrangement” as defined in item 408(c) of Regulation S-K under the Exchange Act.
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name · Title · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares to be Sold · Expiration Date | ||||||
| Allene Diaz | Board Member | Termination | November 17, 2025 | X | 35% of RSUs released | Upon the execution of all instructions included in the plan |
| Joseph Baroldi | Executive Vice President, Chief Business Officer | Termination | November 23, 2025 | X | 87,874 | Upon the execution of all instructions included in the plan |
| Patrick O'Neil | Executive Vice President, Chief Legal Officer and General Counsel | Termination | December 8, 2025 | X | 237,477 | Upon the execution of all instructions included in the plan |
| Joseph Loscalzo | Board Member | Adoption | November 18, 2025 | X | 78,321 | The earlier to occur of (i) January 31, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Eugene Schneider | Executive Vice President, Chief Clinical Development and Operations Officer | Adoption | November 19, 2025 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) February 14, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Joseph Baroldi | Executive Vice President, Chief Business Officer | Adoption | November 25, 2025 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) February 28, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Frank Bennett | Executive Vice President, Chief Scientific Officer | Adoption | November 19, 2025 | X | 85,089 | The earlier to occur of (i) February 1, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Shannon Devers | Executive Vice President, Chief Human Resources Officer | Adoption | November 24, 2025 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) April 4, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Allene Diaz | Board Member | Adoption | November 25, 2025 | X | 68,800 | The earlier to occur of (i) February 28, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Joseph Klein | Board Member | Adoption | November 25, 2025 | X | 62,282 | The earlier to occur of (i) June 30, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Patrick O'Neil | Executive Vice President, Chief Legal Officer and General Counsel | Adoption | December 8, 2025 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) June 1, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Kyle Jenne | Executive Vice President, Chief Global Product Strategy Officer | Adoption | December 8, 2025 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) June 30, 2027, and (ii) Upon the execution of all instructions provided in the plan |
| Brett Monia | Chief Executive Officer | Adoption | December 8, 2025 | X | 260,773 | The earlier to occur of (i) September 30, 2028, and (ii) Upon the execution of all instructions provided in the plan |
| Elizabeth Hougen | Executive Vice President, Finance and Chief Financial Officer | Adoption | December 9, 2025 | X | Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting | The earlier to occur of (i) February 28, 2028, and (ii) Upon the execution of all instructions provided in the plan |
| Joseph Wender | Board Member | Adoption | December 9, 2025 | X | 70,000 | The earlier to occur of (i) December 31, 2026, and (ii) Upon the execution of all instructions provided in the plan |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.